Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2021-02-08 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰自愿披露关于BAT8001临床试验进展的提示性公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by 百奥泰生物制药股份有限公司 regarding the progress of a clinical trial for their drug BAT8001. It provides an update on the clinical trial results and future plans for communication with the regulatory authority (NMPA). The document is short (1037 characters) and focuses on clinical progress and risk disclosure rather than financial data or detailed report content. It is not an annual or interim financial report, nor a regulatory certification or voting result. It is an announcement of clinical trial progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2021-02-08 Chinese
百奥泰自愿披露关于司库奇尤单抗（BAT2306）注射液获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by 百奥泰生物制药股份有限公司 regarding the approval of a clinical trial for a drug (司库奇尤单抗 injection). It includes details about the drug, regulatory approval from the National Medical Products Administration, and risk warnings related to the clinical trial and market competition. The document is short (1290 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed regulatory filing. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-02-07 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from China International Capital Corporation Limited regarding the listing and circulation of restricted shares from the initial public offering of Bio-Thera Solutions Ltd. It references regulatory approvals, lock-up periods, shareholder commitments, and the number and type of shares becoming tradable. The document is not a financial report, earnings release, or management discussion but rather a formal verification and compliance statement related to share circulation post-IPO. This fits the category of a Regulatory Filing (RNS) as it is a compliance and regulatory announcement that does not fit into other specific categories like capital updates or director dealings.
2021-02-05 Chinese
首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming tradable, the lock-up period, shareholder commitments, and regulatory approvals. It does not contain financial statements or detailed financial performance data. The document length is 3575 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on share circulation and shareholder commitments post-IPO, which aligns with a Share Issue/Capital Change announcement rather than an Annual Report, Interim Report, or Earnings Release. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2021-02-05 Chinese
关于2020年年度业绩预亏的更正公告
Regulatory Filings Classification · 95% confidence The document is a correction announcement regarding a previously disclosed 2020 annual performance forecast (业绩预亏公告) by 百奥泰生物制药股份有限公司. It corrects numerical errors in the forecasted net profit figures. The document is short (863 characters) and serves to amend a prior announcement rather than presenting a full annual report or detailed financial statements. It does not contain comprehensive financial data or analysis but is an update/correction to a prior earnings forecast announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and corrections that do not constitute full reports or earnings releases.
2021-02-02 Chinese
2020年年度业绩预亏公告
Earnings Release Classification · 95% confidence The document is a 2020 annual performance forecast announcement by 百奥泰生物制药股份有限公司. It provides preliminary estimated net profit figures for the full year 2020, including expected losses and reasons for changes compared to the prior year. It explicitly states that the forecast is unaudited and that the final audited financial data will be disclosed in the formal 2020 annual report. The document length is short (1115 characters) and it serves as a performance forecast rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a fiscal year but is not the full annual report (10-K) or audited financial statements. It is not a report publication announcement since it contains substantive financial estimates and analysis, not just a notice of report availability. FY 2020
2021-01-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.